Merck & Co., Inc.
RAHWAY, NJ · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$820.3M2026 Q3
Positions13
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.99.9%
What Changed This Quarter?
No notable portfolio changes this quarter.Top Holdings
MRNA
Moderna
54.2%
PSNL
Personalis
27.9%
KYMR
Kymera Therapeutics
10.5%
AKTS
Aktis Oncology
2.3%
EIKN
Eikon Therapeutics
1.6%
TRDA
Entrada Therapeutics
1.3%
ALEC
Alector
0.8%
STRO
Sutro Biopharma
0.5%
New / Increased
0 new · 0 increased
Reduced / Exited
0 reduced · 0 sold out
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.